STXS

Stereotaxis, Inc. 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2004, for Stereotaxis, Inc., a Delaware corporation. The company designs, manufactures, and markets the Stereotaxis System, an advanced cardiology instrument control system that uses magnetic fields to guide catheters and guidewires during interventional procedures. The company recently completed its Initial Public Offering (IPO) in August 2004, raising approximately $41.4 million in net proceeds, and converted all outstanding convertible preferred stock to common stock.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 449% year-over-year for the quarter and 301% for the nine-month period. This was driven by a 504% increase in system sales (6 systems sold in Q3 2004 vs. 1 in Q3 2003) and a 125% increase in disposables and service revenue.
• Expense Increases: Operating expenses rose significantly due to commercialization efforts. Research and Development (R&D) increased 17% for the quarter and 53% for the nine months. Sales and Marketing expenses increased 47% for the quarter and 94% for the nine months, primarily due to hiring additional personnel and expanded marketing programs.
• Liquidity Improvement: Cash and cash equivalents increased from $21.4 million at year-end 2003 to $47.8 million at September 30, 2004, largely due to the IPO proceeds. Working capital improved from $22.8 million to $59.3 million.
• Stock Structure: A 1-for-3.6 reverse stock split was completed in July 2004. All convertible preferred stock was converted to common stock in August 2004.

Guidance, Outlook, and Risks

Outlook: Management expects to incur additional losses through the end of 2005 as the company continues product development, commercialization, and R&D. The company anticipates negative cash flow from operations for the foreseeable future and expects to fund operations using IPO proceeds and existing cash resources.

Key Risks and Contingencies:

• Market Adoption: Success depends on hospitals purchasing the expensive capital equipment and physicians adopting the new technology. Sales cycles are long (6-8 months for installation) and subject to regulatory approvals (Certificate of Need).
• Collaboration Dependence: The company relies on strategic alliances with Siemens, Philips, and Johnson & Johnson for integration, co-marketing, and manufacturing of disposable devices. Failure of these partnerships could materially harm the business.
• Regulatory: Future growth depends on obtaining FDA clearances for new disposable interventional devices. Delays or denials would limit revenue potential.
• Supply Chain: The company relies on contract manufacturers and single-source suppliers for critical components, including magnets sourced from Japan.
• Backlog: As of September 30, 2004, purchase orders and commitments were approximately $20 million, though these are subject to cancellation or delay.

Investor Verification Checklist

• Verify the conversion of all preferred stock to common stock and the impact on share count (27.1 million shares outstanding as of Oct 29, 2004).
• Confirm the status of the $20 million backlog and the timeline for revenue recognition given the long installation cycles.
• Review the progress of FDA clearance applications for new disposable interventional devices, which are critical for recurring revenue.
• Assess the stability of strategic partnerships with Siemens, Philips, and Johnson & Johnson, particularly regarding co-marketing and manufacturing obligations.
• Monitor cash burn rate against the $41.4 million in IPO proceeds to ensure sufficient liquidity through 2005.